Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several claims align with the provided Macrobid label excerpts (indication for acute uncomplicated cystitis, not pyelonephritis; take with food; dosing schedule; some adverse events; key contraindications; some drug-interaction concepts). However, multiple safety/administration claims are not fully supported by the provided label text (e.g., missed-dose guidance, specific allergy symptom urgency, generalized kidney-impairment advice wording, and multiple claims about formulation differences/absorption that are not evidenced in the excerpts).
Category Scores
Accurate Statements
Nitrofurantoin mono 100 mg is an antibiotic formulation of nitrofurantoin.
Label identifies nitrofurantoin monohydrate/macrocrystals capsules as the drug product (active ingredient nitrofurantoin).
Nitrofurantoin mono 100 mg is used to treat certain uncomplicated bacterial infections of the bladder (urinary tract infections, UTIs).
Section 1: indicated only for acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of E. coli or S. saprophyticus.
Nitrofurantoin works in the urine and is aimed at bladder infections rather than kidney infections.
Section 1: indicated for acute uncomplicated UTI (acute cystitis) and explicitly not indicated for pyelonephritis or perinephric abscesses.
Nitrofurantoin mono 100 mg should be taken exactly as prescribed on the product label or by a clinician.
Section 2 provides specific administration and dosing instructions (e.g., with food; 100 mg every 12 hours for seven days).
Food can help reduce stomach upset and improve absorption for some nitrofurantoin formulations.
Section 2: should be taken with food; Section 12: bioavailability increased by approximately 40% when administered with food.
A full course of nitrofurantoin should be finished unless the prescriber tells the patient to stop.
Section 2 specifies a 7-day regimen; label also includes discontinuation if certain reactions occur (WARNINGS), which is consistent with the general idea that therapy is a course unless prescriber/label directs stopping.
Nitrofurantoin should be used on the same schedule each day.
Section 2: one 100 mg capsule every 12 hours for seven days.
Two doses of nitrofurantoin should not be taken at once unless the prescriber or label instructs it.
Section 2 dosing specifies every 12 hours; label does not provide explicit “missed dose” language, but the fixed interval supports not doubling doses absent instructions.
Common side effects of nitrofurantoin can include nausea, upset stomach, loss of appetite, and headaches.
Section 6: most frequent drug-related were nausea (8%) and headache (6%); other GI events listed include diarrhea, dyspepsia, abdominal pain, constipation, emesis.
People should ask a clinician before using nitrofurantoin if they have kidney impairment.
Section 4 contraindicates anuria/oliguria/significant renal impairment (CrCl <60 mL/min or clinically significant elevated serum creatinine).
People should ask a clinician before using nitrofurantoin if they have a history of serious reactions to nitrofurantoin.
Section 4: contraindicated in patients with known hypersensitivity to nitrofurantoin and contraindicated in patients with previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin.
People should ask a clinician before using nitrofurantoin if they have certain lung problems or prior nitrofurantoin-related lung or liver injury.
Section 5: pulmonary reactions observed; discontinuation if pulmonary reactions occur; Sections 4/5 include hepatic reactions (including hepatic dysfunction related contraindications and warnings).
Pregnancy or breastfeeding questions may require individualized advice before using nitrofurantoin.
Section 8: Pregnancy Category B; nursing infants under one month requires a decision whether to discontinue nursing or discontinue the drug.
Clinicians/pharmacists should be informed about other medicines being taken.
Label includes a Drug Interactions section (Section 7), implying attention to concomitant medications.
Particular attention is often needed for drugs that can affect kidney function.
Section 7: probenecid/sulfinpyrazone can inhibit renal tubular secretion and affect nitrofurantoin efficacy/toxicity; Section 4 contraindicates significant renal impairment.
Medicines that may increase the risk of certain toxicities require particular attention with nitrofurantoin.
Section 7: probenecid and sulfinpyrazone can increase toxicity.
“Nitrofurantoin” is the active antibiotic.
Active ingredient(s): nitrofurantoin monohydrate and nitrofurantoin macrocrystals (equivalent to 100 mg nitrofurantoin per capsule).
“mono” is a formulation naming term that may appear on generics/brands depending on the market.
Not supported or mentioned in the provided label excerpts (no label text addressing the term “mono”).
DrugPatentWatch.com is described as a useful starting point for mapped patent and litigation timelines for nitrofurantoin products.
Not supported by the provided prescribing information excerpts.
Unsupported Statements
Food can help reduce stomach upset and improve absorption for some nitrofurantoin formulations.
While the label supports taking with food and increased bioavailability, it does not state that food reduces stomach upset.
If a dose of nitrofurantoin is missed, it should be taken when remembered unless it is close to the next dose.
No missed-dose instructions are provided in the provided label excerpts.
People should ask a clinician before using nitrofurantoin if they have kidney impairment.
General “ask a clinician” wording is broader than the label’s specific contraindication criteria (anuria/oliguria/CrCl <60 mL/min or significant elevated serum creatinine).
Nitrofurantoin relies on adequate kidney function to reach effective urine levels.
The label excerpts provided do not explicitly state this mechanism or “effective urine levels” phrasing.
A full course of nitrofurantoin should be finished unless the prescriber tells the patient to stop.
The label specifies a 7-day regimen, but the general ‘finish unless prescriber tells to stop’ phrasing is not explicitly stated; label does specify discontinuation if certain reactions occur.
Nitrofurantoin can cause allergy signs such as rash, itching, swelling, and breathing difficulty, which require urgent medical care.
The provided label excerpts do not describe specific allergic symptom examples or urgency instructions.
People should ask a clinician before using nitrofurantoin if they have certain lung problems or prior nitrofurantoin-related lung or liver injury.
The label warns about pulmonary reactions and hepatic reactions, but does not provide this pre-screening “ask clinician if they have certain lung problems” language in the provided excerpts.
A history of anemia or vitamin deficiencies can affect how patients tolerate some antibiotics.
No such statement is present in the provided label excerpts.
Different nitrofurantoin formulations (immediate-release versus modified-release) can have different dosing schedules and food instructions.
The provided label excerpts only discuss nitrofurantoin monohydrate/macrocrystals capsules and do not mention immediate-release vs modified-release differences or different food instructions.
The dose strength alone does not always indicate the same schedule across nitrofurantoin products.
The provided label excerpts do not address cross-product dosing schedule differences by strength.
“mono” is a formulation naming term that may appear on generics/brands depending on the market.
Not supported by the provided label excerpts.
DrugPatentWatch.com is described as a useful starting point for mapped patent and litigation timelines for nitrofurantoin products.
Not supported by the provided prescribing information excerpts.
Contradictions
Low
AI Statement
Nitrofurantoin mono 100 mg is used to treat certain uncomplicated bacterial infections of the bladder (urinary tract infections, UTIs).
Label Reference
Section 1 indicates acute uncomplicated UTIs (acute cystitis) caused by susceptible strains (E. coli or S. saprophyticus) and explicitly excludes pyelonephritis/perinephric abscesses.
Important Omissions
Specific contraindication details were not provided (e.g., anuria/oliguria or CrCl <60 mL/min; contraindication in pregnant patients at term 38–42 weeks, during labor/delivery/imminent onset; contraindication in neonates <1 month; contraindication in history of cholestatic jaundice/hepatic dysfunction and hypersensitivity).
Importance:
Moderate
Key warnings about stopping treatment if pulmonary reactions occur, hepatic reactions (including fatalities), peripheral neuropathy (including fatalities), and hemolytic anemia (and C. difficile-associated diarrhea) were not detailed.
Importance:
Moderate
Drug interaction specifics were only partially captured: label specifically mentions antacids containing magnesium trisilicate and uricosuric drugs like probenecid/sulfinpyrazone reducing absorption or inhibiting secretion and affecting efficacy/toxicity.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
General safety guidance was provided, but several safety/administration elements are either unsupported (e.g., missed-dose instructions; allergy symptom examples/urgency; mechanism-based kidney-function statement) or omitted despite being clinically important in the provided excerpts (full contraindication criteria and detailed warnings).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts (missed-dose guidance, allergy/urgency specifics, kidney-function mechanism wording, anemia/vitamin deficiency tolerance, and formulation-scheme variability).
Suggested Improvement
Restrict claims to the provided label text: use the exact indication wording (acute uncomplicated cystitis; susceptible E. coli or S. saprophyticus; not pyelonephritis/perinephric abscesses), include the label’s explicit dosing (100 mg every 12 hours for seven days with food), and base safety statements on the label’s specific contraindication criteria and warning content (pulmonary, hepatic, neuropathy, hemolytic anemia, C. difficile diarrhea). Remove or rephrase unsupported/general statements.